Please login
NASCOLA News - Bulletin Item
  

Posted: Monday, December 30, 2013

Stago Launches New Research Product for Antiplatelet Drug Testing

 

Diagnostica Stago Inc. has introduced a new enzyme-linked immunosorbent assay (ELISA) kit, Cy-Quant VASP/P2Y12 (cat # 01076) which is used to examine platelet responsiveness to specific platelet ADP receptor (P2Y12) antagonists and their in vitro effects.  In this way, this research assay can be used to determine the effectiveness of these anti-P2Y12 drugs such as clopidogrel (Plavix®), prasugrel (Effient®), and ticagrelor (Brilinta®).  The assay is P2Y12-specific and independent of other platelet receptors.  Aspirin and abciximab (ReoPro®) do not interfere.  In addition, platelet count and vWF level do not affect the assay.

 

This research-use-only (RUO) assay protocol is simple.  Small-volume citrated whole blood samples are used to measure intracellular platelet vasodilator-stimulated phosphoprotein (VASP) after exposure to different platelet agonists. 

 

Able to run on any plate reader reporting 450 nm wavelengths, this assay provides the VASP phosphorylation status, which after determination of platelet reactivity index (PRI), is then utilized as a surrogate biomarker for inhibited, activated or resting platelets.  The assay’s superior stability means that samples may be analyzed up to 48 hours after collection, allowing for analysis away from the original site of blood collection.  Individual, breakable wells allow for users to use only those reagents and disposables needed to run the assay, resulting with little or no waste.

 

Stago’s VASP assay is an alternative to traditional functional assays such as platelet aggregometry.  Additionally, this method offers inter-laboratory and day-to-day reproducibility as well as positive and negative threshold determinations.  The Cy-Quant VASP/P2Y12 kit is for research use only in the U.S. and Canada (not for use in diagnostic procedures).

 

About Diagnostica Stago, Inc.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis.  Diagnostica Stago, Inc.  is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products.  For more information about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.

 

PLAVIX is a registered trademark of Bristol-Meyers Squibb/Sanofi Pharmaceuticals Partnership.  EFFIENT is a registered trademark of Eli Lilly and Company.  BRILINTA is a registered trademark of the AstraZeneca group of companies.  ReoPro is a registered trademark of Eli Lilly and Company. 

 

###

 

Contacts:

 

Hamid Erfanian, Director of Marketing

Diagnostica Stago, Inc.

(973) 867-2042

Hamid.Erfanian@us.stago.com